Biotest AG — Board/Management Information 2006

Mar 22, 2006

News Details

Corporate | 22 March 2006 09:21

Biotest AG:Supervisory Board announces early extension of Dr. Michael Ramroth’s (CFO), contract by five years

Corporate-news transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— Supervisory Board announces early extension of Dr. Michael Ramroth’s (CFO), contract by five years Dreieich, 21 March 2006. The Supervisory Board of Biotest AG, Dreieich, extended the contract of Dr. Michael Ramroth (44), which was originally due to expire in February 2007, by a further five years. Dr. Ramroth is responsible for Finance and Central Services (including Legal and Human Resources). In his capacity as CFO, Dr. Ramroth has significantly improved the financial situation of Biotest AG and established a solid foundation for growth. The extension of his contract will ensure the continued confidence of the company’s financial backers and shareholders. About Biotest Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialised in immunology and haematology. In its Pharmaceutical segment, Biotest develops immunoglobulines, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or haematopoietic system. In addition, Biotest also researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and serology and microbiology systems which are used, for example, in blood transfusions. Biotest has around 1,100 employees worldwide and its shares are listed in the Frankfurt Stock Exchange’s Prime Standard. Biotest AG: Tel. +49 6103 801-338 Fax: +49 6103 801-347, e-mail: investor_relations@biotest.de Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de German Securities Code Number, ISIN ordinary shares: 522720, DE0005227201 German Securities Code Number, ISIN preferred shares: 522723, DE0005227235 Listed: Prime Standard/Official market Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart (c)DGAP 22.03.2006 ————————————————————————— language: English emitter: Biotest AG Landsteinerstr. 5 63303 Dreieich Deutschland phone: +49 – 6103 / 801 – 0 fax: +49 – 6103 / 801 – 150 email: mail@biotest.de WWW: www.biotest.de ISIN: DE0005227201, DE0005227235 WKN: 522720, 522723 indexes: stockmarkets: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart End of News DGAP News-Service —————————————————————————